IGFBP3 promoter methylation in colorectal cancer: relationship with microsatellite instability, CpG island methylator phenotype, and p53
- PMID: 18084616
- PMCID: PMC2134905
- DOI: 10.1593/neo.07760
IGFBP3 promoter methylation in colorectal cancer: relationship with microsatellite instability, CpG island methylator phenotype, and p53
Abstract
Insulin-like growth factor binding protein 3 (IGFBP3), which is induced by wild-type p53, regulates IGF and interacts with the TGF-beta pathway. IGFBP3 promoter methylation may occur in colorectal cancer with or without the CpG island methylator phenotype (CIMP), which is associated with microsatellite instability (MSI) and TGFBR2 mutation. We examined the relationship between IGFBP3 methylation, p53 expression, CIMP and MSI in 902 population-based colorectal cancers. Utilizing real-time PCR (MethyLight), we quantified promoter methylation in IGFBP3 and eight other CIMP-high-specific promoters (CACNA1G, CDKN2A, CRABP1, IGF2, MLH1, NEUROG1, RUNX3, and SOCS1). IGFBP3 methylation was far more frequent in non-MSI-high CIMP-high tumors (85% = 35/41) than in MSI-high CIMP-high (49% = 44/90, P < .0001), MSI-high non-CIMP-high (17% = 6/36, P < .0001), and non-MSI-high non-CIMP-high tumors (22% = 152/680, P < .0001). Among CIMP-high tumors, the inverse relationship between MSI and IGFBP3 methylation persisted in p53-negative tumors (P < .0001), but not in p53-positive tumors. IGFBP3 methylation was associated inversely with TGFBR2 mutation in MSI-high non-CIMP-high tumors (P = .02). In conclusion, IGFBP3 methylation is inversely associated with MSI in CIMP-high colorectal cancers, and this relationship is limited to p53-negative tumors. Our data suggest complex relationship between global genomic/epigenomic phenomena (such as MSI/CIMP), single molecular events (e.g., IGFBP3 methylation, TP53 mutation, and TGFBR2 mutation), and the related pathways.
Keywords: CIMP; Colon cancer; IGFBP3; MSI; methylation.
Figures




Similar articles
-
TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer.Hum Pathol. 2007 Apr;38(4):614-20. doi: 10.1016/j.humpath.2006.10.005. Epub 2007 Jan 31. Hum Pathol. 2007. PMID: 17270239
-
18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high.BMC Cancer. 2007 May 2;7:72. doi: 10.1186/1471-2407-7-72. BMC Cancer. 2007. PMID: 17474983 Free PMC article.
-
WRN promoter methylation possibly connects mucinous differentiation, microsatellite instability and CpG island methylator phenotype in colorectal cancer.Mod Pathol. 2008 Feb;21(2):150-8. doi: 10.1038/modpathol.3800996. Epub 2007 Dec 14. Mod Pathol. 2008. PMID: 18084250
-
Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature review.Int J Cancer. 2011 Mar 1;128(5):1080-94. doi: 10.1002/ijc.25432. Int J Cancer. 2011. PMID: 20473920 Free PMC article. Review.
-
Four molecular subtypes of colorectal cancer and their precursor lesions.Arch Pathol Lab Med. 2011 Jun;135(6):698-703. doi: 10.5858/2010-0523-RA.1. Arch Pathol Lab Med. 2011. PMID: 21631262 Review.
Cited by
-
SMO expression in colorectal cancer: associations with clinical, pathological, and molecular features.Ann Surg Oncol. 2014 Dec;21(13):4164-73. doi: 10.1245/s10434-014-3888-y. Epub 2014 Jul 15. Ann Surg Oncol. 2014. PMID: 25023548 Free PMC article.
-
The Interplay Between Non-coding RNAs and Insulin-Like Growth Factor Signaling in the Pathogenesis of Neoplasia.Front Cell Dev Biol. 2021 Mar 9;9:634512. doi: 10.3389/fcell.2021.634512. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 33768092 Free PMC article. Review.
-
Promoter methylation of IGFBP-3 and p53 expression in ovarian endometrioid carcinoma.Mol Cancer. 2009 Dec 11;8:120. doi: 10.1186/1476-4598-8-120. Mol Cancer. 2009. PMID: 20003326 Free PMC article.
-
The Insulin-like Growth Factor System and Colorectal Cancer.Life (Basel). 2022 Aug 20;12(8):1274. doi: 10.3390/life12081274. Life (Basel). 2022. PMID: 36013453 Free PMC article. Review.
-
RAS signaling in colorectal carcinomas through alteration of RAS, RAF, NF1, and/or RASSF1A.Neoplasia. 2008 Jul;10(7):680-6, 2 p following 686. doi: 10.1593/neo.08312. Neoplasia. 2008. PMID: 18592002 Free PMC article.
References
-
- Giovannucci E. Nutrition, insulin, insulin-like growth factors and cancer. Horm Metab Res. 2003;35:694–704. - PubMed
-
- Perks CM, McCaig C, Clarke JB, Clemmons DR, Holly JM. A non-IGF binding mutant of IGFBP-3 modulates cell function in breast epithelial cells. Biochem Biophys Res Commun. 2002;294:988–994. - PubMed
-
- Hong J, Zhang G, Dong F, Rechler MM. Insulin-like growth factor (IGF)-binding protein-3 mutants that do not bind IGF-I or IGF-II stimulate apoptosis in human prostate cancer cells. J Biol Chem. 2002;277:10489–10497. - PubMed
-
- Hanafusa T, Yumoto Y, Nouso K, Nakatsukasa H, Onishi T, Fujikawa T, Taniyama M, Nakamura S, Uemura M, Takuma Y, et al. Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma. Cancer Lett. 2002;176:149–158. - PubMed
-
- Tomii K, Tsukuda K, Toyooka S, Dote H, Hanafusa T, Asano H, Naitou M, Doihara H, Kisimoto T, Katayama H, et al. Aberrant promoter methylation of insulin-like growth factor binding protein-3 gene in human cancers. Int J Cancer. 2007;120:566–573. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous